Pfenex Inc. filed with the SEC for an initial public offering (IPO) of up to $74.75 million, aiming to finance a planned phase III trial of lead candidate PF582, a biosimilar to Lucentis (ranibizumab, Genentech Inc./Novartis AG). Filing as an emerging growth company, San Diego-based Pfenex set its sights on the big board, with plans to list on the New York Stock Exchange as PFNX.